In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in pediatric ICU utilization.
This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...
Seasonal maternal RSV vaccination may be cost-effective, particularly for those with higher risks. HealthDay News — Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab ...
Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...
The researchers found that 45,693 outpatient visits, 15,866 emergency department visits, and 7571 hospitalizations among infants would be prevented each year by year-round maternal vaccination.